Stellaria dichotoma (Yinchaihu / Stellariae Radix): A Comprehensive Reference
1. Identity and Botanical Description
1.1 Taxonomic and Nomenclatural Identity
Stellaria dichotoma L. var. lanceolata Bge. (2n=2x=28) is a perennial herb belonging to the family Caryophyllaceae, traditionally employed in Chinese medicine for treating deficiency-related fever. The plant is the official source material for the traditional Chinese medicine drug known as Yinchaihu (银柴胡) or, in pharmacopoeial nomenclature, Stellariae Radix (Radix Stellariae). It is the original plant of the traditional Chinese medicine Yinchaihu (Stellaria Radix) and is mainly distributed in the arid desert areas of northwest China, representing the genuine medicinal material and characteristic cultivated crop in Ningxia.
The full accepted scientific name is Stellaria dichotoma L. var. lanceolata Bunge. The species epithet dichotoma refers to the plant's characteristic dichotomously branched growth habit. Within the broader genus Stellaria, which encompasses the well-known common chickweed (Stellaria media), the var. lanceolata is the pharmacopoeially recognized variety for medicinal root production. Common English names include Lanceolate Dichotomous Starwort Root and Stellaria Root.
1.2 Morphological Description
Stellaria dichotoma var. lanceolata is a perennial herb (19–30 cm tall) exhibiting distinctive morphological features, including a dichotomously branched spreading habit with swollen nodes, a robust taproot system, lanceolate leaves (0.2–2.5 mm long, 1.5–5 mm wide) bearing glandular hairs, white flowers with two-cleft petals and 10 stamens, wide ovate capsules (~3 × 3 mm), and blackish-brown warty seeds. The flowering period extends from May to June, with fruit maturation occurring from July to August.
The commercial crude drug (Stellariae Radix) is characterised by a specific macroscopic appearance. The root is cylindrical, occasionally branched, 15–40 cm long, 1–2.5 cm in diameter, externally pale yellow or yellowish white with twisted longitudinal wrinkles, scars of lateral roots, and pitted hollows from which powder spreads; brown splits are observed, and the apex bears close aggregated warty traces of stems. Texture is hard and fragile, easily broken; the fracture is split, bark fairly thin, wood with radiate striations alternating between yellow and white in colour.
1.3 Geographical Distribution and Habitat
As a typical xerophytic species, Yinchaihu naturally inhabits rocky slopes at elevations of 1,200–3,000 m and thrives in infertile sandy soils. SDL is mainly distributed in semi-arid and arid areas in China and is concentrated in Ningxia, Inner Mongolia, and Shanxi. It is primarily found growing in dry grasslands and rock crevices in regions including Shaanxi, Gansu, Ningxia, and Inner Mongolia.
1.4 Cultivation Status and Commercial Forms
Over the past few decades, with the scarcity of SDL wild resources, people began to explore cultivation and production methods. Following the successful introduction and domestication of YCH in Ningxia in the 1980s, the source of Yinchaihu medicinal materials gradually shifted from wild to cultivated material. Cultivated Yinchaihu has become a main source of production to alleviate the shortage of wild plant resources.
The official medicinal part is the root, harvested as a dried crude drug. The drug is collected in spring and summer when the plant sprouts, or after autumn when stems and leaves wither; it is then removed from rootlets and soil and dried in the sun. Commercially, the roots are typically encountered as:
- Dried whole or sliced root (crude drug) for decoction
- Aqueous or hydroethanolic decoctions prepared by boiling
- Standardised dry extracts incorporated into proprietary traditional Chinese medicine (TCM) patent formulations
- Powdered root material for encapsulation
The content of methanol extracts of both wild and cultivated Yinchaihu exceed the standard content of the Chinese Pharmacopoeia; however, the contents of total sterols and total flavonoids in wild material are significantly higher than those in cultivated material. This difference has relevance for standardisation and quality control of commercial preparations.
2. Traditional and Historical Use
2.1 Primary Traditional Chinese Medicine Uses
Radix Stellariae (RS), also called Yinchaihu, the root of Stellaria dichotoma, is a common Chinese herbal medicine used clinically to treat fever and infantile malnutrition. RS was first described in Ben Cao Gang Mu (Compendium of Materia Medica) approximately 400 years ago. Ben Cao Gang Mu is the monumental pharmacopoeial encyclopaedia compiled by Li Shizhen during the Ming dynasty (completed 1578, first published 1596), which remains a foundational reference for classical TCM pharmacology.
Within the conceptual framework of TCM, Stellaria dichotoma has a long-standing historical use for various conditions, but its primary indications in classical TCM texts are for fever due to yin deficiency, night sweats, and chronic low-grade fevers in children. The herb is classified as clearing deficient heat (qingxu re) — a category that specifically addresses low-grade, persistent, or afternoon fevers arising from insufficiency of yin fluid rather than exogenous pathogens.
In classical TCM classification, the herb is sweet and bitter in taste and cool in nature. Its primary action is to clear deficient heat, used for fever or heat from yin deficiency, chronic low-grade fever, malarial fevers with deficiency, and consumption known as "Steaming Bone Disorder." Secondary indications include clearing heat to stop bleeding (uterine bleeding from blood heat, coughing blood, blood in the urine) and clearing heat in the context of resolving childhood nutritional impairment (fever, thirst, weakness, and irritability in children from poor nutrition, including infantile malnutrition and hyperactivity in children related to poor diet).
Stellaria dichotoma var. lanceolata, a member of the Caryophyllaceae, is a traditional herbal medicine that has been used to treat fever, night sweats, and malaria in East Asia. Its root has been used in herbal formulae for treating asthenic-fever, infection, malaria, dyspepsia in children, and several other symptoms.
2.2 Classical Herbal Combinations
Within the multi-herb prescriptions characteristic of TCM practice, Yinchaihu has historically been combined with complementary herbs. Classical combinations include: for Steaming Bone Disorder, Stellaria (Yin Chai Hu) with Picrorhiza (Hu Huang Lian); and for recurring afternoon fever from deficiency, Stellaria with Lycium bark (Di Gu Pi). Some herbal formulas containing Stellaria dichotoma are used in broader patterns where digestive weakness and poor appetite are present, particularly in pediatric populations with low-grade fevers and digestive complaints.
2.3 Geographical Extent of Traditional Use
In East Asia, a variety of herbal extracts, including those from Stellaria dichotoma, have been used to treat fever-related illnesses, such as influenza and malaria. Use is attested principally in Chinese medical traditions including mainland China, and the herb is also referenced in Tibetan medicine, where it appears in formulas for lung fever and pneumonia, as recorded in classical Tibetan materia medica sources.
3. Key Constituents and Phytochemistry
3.1 Overview of Chemical Classes
Stellaria dichotoma var. lanceolata is a traditional Chinese medicinal plant of Caryophyllaceae that contains many chemicals, such as β-carboline alkaloids, sterols, cyclic peptides, phenolic acids, and flavonoids, which have been used as folk medicines for antifebrile purposes, and which inhibit cell growth, cyclooxygenase activity, and also exhibit anti-inflammatory, anti-allergic, vasodilator, and other effects. The roots represent the primary repository of these bioactive metabolites. A comprehensive metabolomic analysis identified 1,586 metabolites in different origins, classified into thirteen categories including lipids, organic acids, and organic heterocyclic compound derivatives.
3.2 β-Carboline Alkaloids
The β-carboline alkaloids represent the most extensively studied and structurally diverse class of compounds in S. dichotoma. From the aqueous ethanolic extract, new β-carboline-type alkaloids, dichotomines A, B, C, and D, and dichotomides I and II, were isolated. Subsequent investigations revealed a substantially larger alkaloid complement: investigation of the chemical constituents of the roots of Stellaria dichotoma var. lanceolata resulted in the isolation of 21 β-carboline alkaloids, including 13 new compounds, dichotomides III–XIV and dichotomine E, and eight known compounds.
Additional β-carboline alkaloids continued to be identified in later studies. Five new β-carboline-type alkaloids, dichotomines F–J, along with nine known compounds including dichotomides I, III, V, and VII, stellarines A and C, dichotomine B, glucodichotomine B, and 1-acetyl-3-carboxy-β-carboline, were isolated from the roots.
Furthermore, new glycosides of β-carboline-type alkaloid, neolignan, and phenylpropanoid have been isolated: a new β-carboline-type alkaloidal glycoside, glucodichotomine B, four new neolignan glycosides, dichotomosides A, B, C, and D, and a new phenylpropanoid glycoside, dichotomoside E, were isolated from the roots of Stellaria dichotoma L. var. lanceolata. Specific β-carboline alkaloids identified by LC–HRMS analysis include stellarines A, B, and C; dichotomine B, H, and L; and glucodichotomine B.
3.3 Sterols
Sterols represent another major and pharmacologically relevant constituent class. From the ether-soluble fraction of the aqueous extract of the roots, a mixed compound of α-spinasterol and stigmast-7-enol, its palmitate, furan-3-carboxylic acid, and a flavone derivative, wogonin, were isolated. α-Spinasterol (stigmasta-7,22-dien-3β-ol) is considered a principal marker compound. It has been reported that RS contains a higher content of α-spinasterol, which possesses anti-inflammatory and antipyretic effects. The metabolite β-sitosterol has also been identified among the significantly differing compounds between wild and cultivated sources, along with quercetin derivatives and newly discovered potential active components such as trigonelline, arctiin, and loganic acid.
3.4 Cyclic Peptides (Dichotomins)
A chemically distinctive and pharmacologically notable series of cyclic peptides has been characterised from the roots. New cyclic penta- or hexapeptides — dichotomins A, B, C, D, and E [A: cyclo(-Gly-Thr-Phe-Leu-Tyr-Val-); B: cyclo(-Gly-Thr-Phe-Leu-Tyr-Thr-); C: cyclo(-Gly-Thr-Phe-Leu-Tyr-Ala-); D: cyclo(-Gly-Val-Gly-Phe-Tyr-Ile-); E: cyclo(-Gly-Tyr-Ala-Phe-Ala-)] — have been isolated from the roots of Stellaria dichotoma L. var. lanceolata Bge., with structures elucidated by extensive 2D NMR, chemical degradation, and X-ray crystallographic analysis. Two further new cyclic peptides, dichotomins F and G, have been isolated from the roots, and their structures were elucidated by chemical degradation, ESIMS–MS, and extensive 2D NMR methods. Additional cyclic octapeptides, dichotomin H, cyclo(-Ala-Pro-Thr-Phe-Tyr-Pro-Leu-Ile-), and dichotomin I, cyclo(-Val-Pro-Thr-Phe-Tyr-Pro-Leu-Ile-), have also been isolated from the roots.
3.5 Flavonoids and C-Glycosylflavonoids
From the n-BuOH soluble fraction of the aqueous extract of roots of Stellaria dichotoma L. var. lanceolata, two new C-glycosylflavonoids were isolated; their chemical structures were established as 6,8-di-C-galactopyranosylapigenin and 6-C-galactopyranosylisoscutellarein by chemical and physical analyses. The flavonoid wogonin was also identified in ether-soluble root fractions. These compounds contribute to the total flavonoid content, which is employed as one of the quality-control parameters in the Chinese Pharmacopoeia monograph.
3.6 Other Constituents
Additional phytochemicals identified in S. dichotoma roots include phenolic acids, fatty acids, and furan derivatives. Diverse compositions including flavonoids, sterols, cyclic peptides, and β-carboline-type alkaloids in Stellaria dichotoma are important for its biological activities. The 2022 comprehensive metabolomic study further found that in total, 1,586 metabolites were identified by mass spectrometry, and 97 were significantly different between wild and cultivated sources, including β-sitosterol and quercetin derivatives, as well as newly discovered potential active components such as trigonelline, arctiin, and loganic acid.
4. Established Mechanisms of Action
4.1 Anti-Inflammatory Mechanisms
Among the isolated β-carboline alkaloids, five compounds were examined for their anti-inflammatory potential via inhibition of nitric oxide (NO) production in LPS-treated RAW 264.7 cells; all compounds tested exhibited significant inhibition of NO production, with IC50 values in the range of 11.3 to 19.3 μM. This action is consistent with interference in the NF-κB/iNOS pathway, the central pro-inflammatory signalling axis activated by bacterial lipopolysaccharide.
At the mechanistic level, in primary murine macrophages, Mycobacterium abscessus infection resulted in the rapid activation of NF-κB and mitogen-activated protein kinase (MAPK), as well as in the generation of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6, which were all significantly inhibited by pretreatment with Stellaria dichotoma var. lanceolata extract. The inhibition of NF-κB and MAPK pathways represents a plausible molecular basis for the herb's observed anti-inflammatory effects.
α-Spinasterol, present in high content in the root, possesses anti-inflammatory and antipyretic effects. This phytosterol is a known cyclooxygenase (COX) inhibitor, consistent with the anti-inflammatory and antipyretic properties attributed to the herb in both traditional and experimental contexts.
4.2 Anti-Allergic Mechanisms
The aqueous ethanolic extract from the roots of Stellaria dichotoma showed an antiallergic effect on ear passive cutaneous anaphylaxis (PCA) reaction in mice (in vivo) and inhibitory activity on the release of β-hexosaminidase in RBL-2H3 cells (in vitro). β-Hexosaminidase release is a standard marker of mast cell degranulation; its inhibition indicates suppression of the immediate (early) phase of type I (IgE-mediated) allergic reactions.
Among the isolated β-carboline alkaloids, dichotomine C was found to show inhibitory activity on β-hexosaminidase release (IC50 = 62 μM). Moreover, dichotomine C also inhibited antigen-IgE-mediated TNF-α and IL-4 releases (IC50 = 19 and 15 μM respectively) in RBL-2H3 cells, both of which participate in the late phase of type I allergic reactions.
Among the neolignan and phenylpropanoid glycosides, dichotomoside D inhibited the release of β-hexosaminidase (IC50 = 64 μM) as well as tumour necrosis factor-α and interleukin-4 (IC50 = 16 and 34 μM) in RBL-2H3 cells. These findings suggest that dichotomoside D is more effective against the late-phase reactions in type I allergy than in the immediate phase.
4.3 Antipyretic Mechanisms
Although clinical and pharmacological studies confirm Yinchaihu's antipyretic efficacy, the molecular basis and mechanisms of action remain incompletely characterised. The presence of α-spinasterol, a phytosterol with documented COX-inhibitory and antipyretic properties, is the most plausible mechanism so far identified for its fever-clearing action. COX inhibition reduces prostaglandin E2 synthesis, thereby lowering the hypothalamic thermoregulatory set-point.
4.4 Metabolic and Energy-Regulating Mechanisms
In a murine model of high-fat diet feeding, the Radix Stellariae extract increased body temperature in obese mice and the expression of uncoupling proteins (UCPs) and peroxisome proliferator-activated receptors (PPARs) in white adipose tissue, suggesting that it alleviated metabolic disorders by potentially activating UCP and PPAR signalling. This mechanism — thermogenic uncoupling and PPAR-mediated lipid metabolism — represents a novel axis distinct from the herb's classical TCM indications.
4.5 Anti-Atrophic Mechanisms (Skeletal Muscle)
A 2025 study investigated the protective effects of Stellaria dichotoma root extract and its isolated bioactive compounds during muscle atrophy using both in vitro and in vivo experimental models; root extract prevented dexamethasone-induced atrophy in C2C12 myotubes. Dichotomine B was identified as the most abundant and bioactive constituent; treatment with dichotomine B significantly preserved the myotube diameter, enhanced the fusion index, and maintained the myosin heavy chain protein level while suppressing key atrophic biomarkers, including FoxO3a, MuRF-1, and Atrogin-1, in dexamethasone-treated myotubes. The FoxO3a/MuRF-1/Atrogin-1 axis is the canonical ubiquitin-proteasome pathway mediating skeletal muscle proteolysis and atrophy.
4.6 Antioxidant Mechanisms
Enzymatic extracts of S. dichotoma have been shown to possess strong antioxidant activity in DPPH, hydroxyl, and alkyl radical scavenging assays. The results indicated that enzymatic extracts are able to inhibit the radical-associated oxidative damage of DNA as evidenced through measurement of supercoiled pBR322 plasmid DNA to the open circular form; enzymatic extracts dose-dependently protected against hydroxyl-radical-induced DNA damage.
4.7 Vasodilatory Mechanisms
New cyclic peptides extracted from Radix Stellariae have been demonstrated with antitumor activity in vitro and mild dilation of blood vessels. The vasodilatory cyclic peptides dichotomin J and K have been isolated from S. dichotoma and have demonstrated a vasorelaxant effect on rat aorta tissue. The molecular basis of this vasorelaxation has not been fully characterised in published literature.
5. Scientific Evidence by Area of Application
5.1 Anti-Inflammatory Activity
Evidence type: Predominantly in vitro and animal models; no controlled human clinical trials identified.
Multiple isolated phytochemical studies have demonstrated anti-inflammatory activity in cell-based systems. Investigation of the roots' chemical constituents yielded 21 β-carboline alkaloids; five compounds tested for anti-inflammatory potential in LPS-treated RAW 264.7 macrophage cells exhibited significant inhibition of NO production, with IC50 values of 11.3 to 19.3 μM. The study design was an in vitro pharmacological screen using murine macrophage-like cells — a standard preliminary model for anti-inflammatory drug discovery — and does not constitute clinical evidence.
In vivo animal evidence is available from an infection model: an herbal extract from Stellaria dichotoma var. lanceolata effectively attenuated inflammatory responses during Mycobacterium abscessus infection. The 70% ethanol extract reduced mortality in Mycobacterium abscessus-infected mice while mitigating associated inflammatory responses. These results are limited to a single infectious disease model in rodents and cannot be extrapolated to general anti-inflammatory use in humans.
Multiple alkaloids within Yinchaihu possess potent anti-inflammatory activity; although clinical and pharmacological studies confirm its antipyretic efficacy, the molecular basis and mechanisms of action remain incompletely characterised. Overall, the anti-inflammatory evidence base is preliminary — it is informative regarding plausible mechanisms but lacks the human clinical data needed to substantiate therapeutic claims.
5.2 Antipyretic Activity
Evidence type: Historically documented in TCM clinical practice; pharmacological confirmation limited to animal and cell-based models.
Clinical and pharmacological studies confirm Yinchaihu antipyretic efficacy, though no large-scale, placebo-controlled randomised clinical trial specifically evaluating Yinchaihu monotherapy for fever has been identified in the peer-reviewed literature. The antipyretic effect is the most historically consistent and documented application of this herb across multiple centuries of TCM use, and it is the primary indication recognised in the Chinese Pharmacopoeia. The principal mechanism proposed is α-spinasterol-mediated inhibition of cyclooxygenase, reducing prostaglandin synthesis, though this mechanism has not been definitively confirmed through clinical pharmacodynamic studies.
5.3 Anti-Allergic Activity
Evidence type: In vitro cell assays and rodent in vivo model; no human clinical trials identified.
The aqueous ethanolic root extract showed an antiallergic effect on ear passive cutaneous anaphylaxis (PCA) reaction in mice in vivo and inhibitory activity on the release of β-hexosaminidase in RBL-2H3 cells in vitro. The PCA test is a standard rodent model of IgE-mediated type I hypersensitivity; positive results in this model provide preliminary mechanistic plausibility but do not constitute clinical evidence for treating allergic disease in humans. β-Carboline alkaloids in the extract have demonstrated anti-allergy properties through the mice anti-allergic reaction experiment. The anti-allergic evidence is entirely preclinical and should be characterised as hypothesis-generating rather than clinically validated.
5.4 Metabolic Effects (Anti-Obesity / Metabolic Syndrome)
Evidence type: Single animal study (mice); no human clinical data.
A study in PeerJ (2017) investigated whether Radix Stellariae extract alleviates metabolic disorders; results indicated that the extract significantly inhibited body weight gain in high-fat diet-fed C57BL/6 mice, reduced fasting glucose levels, and improved insulin tolerance. Moreover, the extract increased body temperature in the mice and the expression of uncoupling proteins and peroxisome proliferator-activated receptors in white adipose tissue, suggesting alleviation of metabolic disorders by potentially activating UCP and PPAR signalling. This is a single preclinical study using an inbred mouse strain on a high-fat diet. Results must be viewed as preliminary; translation to humans requires dedicated clinical study.
5.5 Anti-Cancer / Cytotoxic Activity
Evidence type: In vitro cytotoxicity studies only; no human clinical data.
RS has several pharmacological functions including anti-cancer activities according to cited studies. New cyclic peptides extracted from Radix Stellariae have been demonstrated with antitumor activity in vitro. Certain β-carboline compounds (dichotomines) exhibit moderate cytotoxicity in cell line assays. In vitro cytotoxicity in cancer cell lines is the weakest level of pre-clinical evidence for anti-cancer activity; the substantial majority of compounds active in such models fail in subsequent animal and human testing. No animal tumour models or clinical oncology studies for S. dichotoma have been identified in the peer-reviewed literature.
5.6 Antimicrobial / Infection-Protective Activity
Evidence type: In vitro and rodent infection model (Mycobacterium abscessus); no human clinical data.
A herbal extract from Stellaria dichotoma var. lanceolata effectively attenuated inflammatory responses from infection of Mycobacterium abscessus (Mab), but not Toxoplasma gondii. The 70% ethanol extract reduces mortality in Mycobacterium abscessus-infected mice while mitigating associated inflammatory responses. These findings are specific to a non-tuberculous mycobacterium in a mouse model. The absence of activity against Toxoplasma gondii in the same study illustrates selectivity and limits broad characterisation as a general anti-infective agent.
5.7 Skeletal Muscle Atrophy Protection
Evidence type: Recent in vitro and in vivo animal study (2025); no human clinical data.
A 2025 study investigated the protective effects of Stellaria dichotoma root extract and its isolated bioactive compounds during muscle atrophy using both in vitro and in vivo experimental models; root extract prevented dexamethasone-induced atrophy in C2C12 myotubes. Dichotomine B reduced proteolysis in serum-free cultured C2C12 myotubes and in mice subjected to 48 hours of fasting, preserving muscle mass and strength; these findings suggest that S. dichotoma root extract and its principal compound dichotomine B have promising therapeutic potential and provide an opportunity to develop novel pharmacological interventions against muscle wasting. This is a very recent finding at the preclinical stage, and human relevance remains to be established.
5.8 Antioxidant Activity
Evidence type: In vitro radical-scavenging assays; no clinical data.
Enzymatic extracts of S. dichotoma have been shown to possess strong antioxidant activity in DPPH, hydroxyl, and alkyl radical scavenging assays; results indicated that enzymatic extracts are able to inhibit the radical-associated oxidative damage of DNA as evidenced through measurement of supercoiled pBR322 plasmid DNA conversion to the open circular form. In vitro antioxidant assays (DPPH, ORAC, etc.) are widely criticised as poor predictors of in vivo antioxidant effects. These results have not been validated in clinical studies.
6. Body Systems and Health Areas Associated with Stellaria dichotoma
Based on the totality of traditional use documentation and current scientific literature, S. dichotoma has been associated with the following body systems and health domains:
- Thermoregulatory system / Fever management: The primary historical and pharmacopoeial indication; the best-documented area of use.
- Immune and inflammatory system: In vitro and animal evidence for anti-inflammatory and anti-allergic effects via NF-κB, MAPK, and mast cell degranulation pathways.
- Musculoskeletal system: Emerging preclinical evidence for skeletal muscle atrophy prevention (dichotomine B; 2025 study).
- Metabolic / Endocrine system: Preclinical evidence for anti-obesity effects via UCP/PPAR activation.
- Cardiovascular system: Vasorelaxant cyclic peptides (dichotomins J and K) identified in vitro and in isolated rat aorta models.
- Paediatric / Nutritional health: Traditional use for infantile fever and malnutrition-related conditions; consistent across classical TCM texts.
- Respiratory system: Traditional use in multi-herb formulas for lung fever and cough; limited scientific research directly linking Stellaria dichotoma with the treatment or support of asthma has been conducted.
- Gastrointestinal system: Use in digestive contexts is primarily based on traditional theories and clinical experience rather than robust scientific studies; there is a lack of high-quality scientific research verifying efficacy for digestive health.
7. Dosage Forms and Reported Dosages
No independently conducted dose-finding clinical trials for Stellaria dichotoma monotherapy were identified in the retrieved peer-reviewed literature. Dosage information derives from pharmacopoeial standards (Chinese Pharmacopoeia) and from doses used in preclinical studies.
7.1 Traditional / Pharmacopoeial Dosage (Decoction)
The Chinese Pharmacopoeia (2020 edition) lists Stellariae Radix as an official drug. The conventional decoction dose employed in TCM clinical practice is typically stated as 3–9 g of dried root per day, prepared as a water decoction; this figure is consistent with standard TCM prescribing practice for heat-clearing root drugs, though specific dose values in the retrieved primary literature sources were not directly quoted. The drug is generally administered as part of multi-herb formulae rather than as a single-ingredient decoction.
7.2 Doses Used in Preclinical Studies
In the published murine obesity study, the study investigated whether the RS extract alleviates metabolic disorders; results indicated that RSE significantly inhibited body weight gain in high-fat diet-fed C57BL/6 mice, reduced fasting glucose levels, and improved insulin tolerance. The specific mg/kg dose used in that study is not directly quotable from the available abstract text. In the muscle atrophy study, dichotomine B reduced proteolysis in serum-free cultured C2C12 myotubes and in mice subjected to 48 hours of fasting, preserving muscle mass and strength; the precise administered dose in mg/kg is not available from retrieved sources.
7.3 In Vitro Concentrations
In cell-based anti-inflammatory studies, five β-carboline alkaloids showed significant inhibition of NO production in LPS-treated RAW 264.7 cells at IC50 values in the range of 11.3 to 19.3 μM. In anti-allergic cell assays, dichotomine C showed inhibitory activity on β-hexosaminidase release (IC50 = 62 μM) and inhibited antigen-IgE-mediated TNF-α and IL-4 (IC50 = 19 and 15 μM respectively). These in vitro IC50 values cannot be translated directly to human dosing recommendations without pharmacokinetic data.
7.4 Quality Control Standards
The content of methanol extracts of both wild and cultivated Yinchaihu exceed the standard content defined by the Chinese Pharmacopoeia; however, the contents of total sterols and total flavonoids in wild material are significantly higher than those in cultivated material. This differential is pharmacopoeially relevant because total sterol content (principally α-spinasterol) is used as a marker for assessing raw material quality.
8. Safety Considerations and Quality Issues
8.1 Adulteration and Misidentification
A documented and practically significant safety concern for Stellaria dichotoma is adulteration and misidentification in commercial markets. Tools enabling discrimination of authentic S. dichotoma from common adulterants (Stellaria media) address critical quality control needs in traditional Chinese medicine supply chains, ensuring therapeutic consistency.
A particularly important confound involves confusion with the root of Codonopsis pilosula (Dangshen). Although the two herbs belong to different plant families and their effects and clinical pharmacological actions are different, the medicinal parts of both are all dried roots and have similar macroscopic and microscopic features such as cylindrical shape, yellowish-brown surface with longitudinal wrinkles, more than 10 rows of cork cells, and sieve tube clusters; it is therefore very easy to confuse them in the herb market and clinical use. A 2024 study from the National Institutes for Food and Drug Control (China) found that 1 of 12 batches of market samples was identified as an adulterated sample using digital chemical profiling methods.
8.2 Wild vs. Cultivated Material Differences
While both wild and cultivated material meets the Chinese Pharmacopoeia's minimum standard for methanol-extract content, total sterols and total flavonoids are significantly higher in wild material than in cultivated material. This raises questions about the comparative therapeutic potency of cultivated-source products, which now dominate commercial supply.
8.3 Geographic Origin and Habitat Effects on Composition
Analysis of metabolites from nine different production areas showed that habitat factors significantly affect the metabolite profile; 1,586 metabolites were identified and classified into thirteen categories. This chemical variability across origins has implications for reproducibility of biological effects and standardisation of commercial preparations.
8.4 Pharmacopoeial Recognition and Regulatory Status
Stellariae Radix is an officially listed drug in the Chinese Pharmacopoeia (2020 edition), setting quality standards for the crude drug including standards for total sterol content, methanol-extract yield, and macroscopic and microscopic identification. Yinchaihu (Stellaria Radix, 2n=2x=28) is a perennial herb belonging to the Caryophyllaceae family, traditionally employed in Chinese medicine for treating deficiency-related fever. There is no European Pharmacopoeia monograph, no ESCOP monograph, and no German Commission E monograph for this species as of current available sources. The NIH/NCCIH, WHO, and EMA have not published standalone monographs on this ingredient.
8.5 Absence of Clinical Toxicology Data
No formal clinical toxicology studies, maximum tolerated dose studies, or pharmacovigilance data for Stellaria dichotoma mono-preparations in humans were identified in the peer-reviewed literature retrieved. The herb's long history of use in TCM formulae provides indirect evidence of tolerability at traditional doses, but systematic safety data and drug interaction studies are absent. Multiple alkaloids within Yinchaihu possess potent anti-inflammatory activity; although clinical and pharmacological studies confirm antipyretic efficacy, the molecular basis and mechanisms of action remain incompletely characterised. This mechanistic incompleteness applies equally to the safety profile.
8.6 Evidence Gaps and Research Limitations
The entirety of the scientific evidence for S. dichotoma's pharmacological effects rests on in vitro studies, preclinical animal experiments, and TCM clinical experience. Despite its traditional use in formulations for general pain or inflammation, there is a lack of robust scientific research directly supporting specific efficacy claims; published pharmacological studies focus mainly on anti-inflammatory and antioxidant properties in vitro or in animal models, but these do not address human clinical outcomes. No randomised controlled trials, systematic reviews, or meta-analyses of human clinical studies for any specific condition were identified. The absence of prospective human clinical data is the central limitation of the evidence base for this ingredient.
References
Go back